ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Stopped Enrollment was closed after the open label stage due to poor recruitment rate (randomized stage never opened).

Conditions

• Neoplasms, Breast

Interventions

• DRUG: lapatinib
• DRUG: paclitaxel
• DRUG: trastuzumab

Sponsor

Novartis Pharmaceuticals